BTK and neoplasm: The calculated tumor response rates for TL-895 and acalabrutinib (both 24%) suggest that these two second-generation BTK inhibitors have superior efficacy in these DLBCL PDX models; for acalabrutinib, the rate is consistent with clinical observations in patients with either ABC- or GCB-DLBCL (combined overall response rate [ORR] of 24%32).